Genentech Submits BLA for Advanced Breast Cancer Drug

Genentech has submitted a BLA for its advanced HER2-positive breast cancer drug trastuzumab-DM1, a combination of Genentech’s Herceptin and ImmunoGen’s cancer-killing agent DM1, as a third-line treatment for breast cancer. The submission is based on results of a 110-patient, Phase II study that showed the drug shrank tumors in one-third of women who had received, on average, seven prior medicines for advanced HER2-positive breast cancer, Genentech said.
Drug Industry Daily